Engineered HLA Panels for High-Resolution Epitope Mapping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HLA panels, particularly Single Antigen Bead (SAB) assays, are limited by the number and nature of included HLA antigens, leading to deficient and uncertain reactivity patterns, and lack sufficient resolution to differentiate immunogenic mismatches in transplant recipients, which impacts transplant outcomes.
Innovation Solution
The development of HLA panels incorporating engineered variants (EV) that include altered functional epitopes, allowing for enhanced resolution and coverage of variant positions, and the use of computer-implemented algorithms to identify essential residues (ER) recognized by antibodies, providing improved immunogenicity prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional HLA panels with limited antigens are used, then the assay is simpler and cheaper, but the reactivity pattern resolution is deficient and cannot reliably differentiate immunogenic mismatches
Solution Approach 1:
The patent segments the HLA antigen panel into two distinct components: wild-type HLA antigens and engineered variant HLA antigens. This segmentation allows the panel to provide both comprehensive epitope coverage (improving measurement precision) and systematic organization (managing device complexity). The engineered variants are specifically designed to probe particular epitopes, enabling high-resolution reactivity pattern analysis without requiring an exhaustive list of all possible HLA antigens.
Solution Approach 2:
The patent applies parameter changes by modifying HLA antigen sequences to create engineered variants with altered epitopes. These parameter changes in antigen structure enable the detection of specific antibody-epitope interactions that would be indistinguishable using traditional panels. The controlled modification of antigen parameters (amino acid sequences) provides the resolution needed to differentiate immunogenic mismatches while maintaining panel manageability.
2Loss of information
If high-resolution typing is used, then exact amino acid mismatches are revealed, but immunogenicity information is not provided
Solution Approach 1:
The patent introduces engineered variant HLA antigens as intermediaries between high-resolution typing and immunogenicity assessment. These engineered antigens serve as mediators that bridge the gap between knowing the amino acid sequence (typing information) and understanding the immune response risk (immunogenicity). By using these intermediary antigens in the panel, the system can infer immunogenicity from reactivity patterns without directly measuring immune responses.
Solution Approach 2:
The patent performs preliminary action by pre-characterizing the reactivity profiles of engineered variant antigens with known epitopic specificities. This preliminary work establishes a reference framework that allows rapid immunogenicity assessment in clinical settings. The预先 established reactivity patterns serve as a foundation for interpreting patient serum reactivity, eliminating the need for complex real-time immunogenicity measurements.
3Quantity of substance
If more HLA antigens are included in the panel, then better coverage is achieved, but interpretation of reactivity patterns becomes more uncertain
Solution Approach 1:
The patent applies local quality by assigning specific functional roles to different panel components. Wild-type HLA antigens provide baseline reactivity patterns, while engineered variant antigens provide targeted epitope-specific information. This local differentiation of antigen functions within the panel enables reliable interpretation because each antigen type contributes specific, non-redundant information. The systematic organization of diverse antigens with defined roles improves interpretability despite the increased quantity and diversity of panel components.
Data Source
AI summary
Materials and methods for generating a panel including human leukocyte antigens (HLA) and engineered variants (EVs) thereof, as well as diagnostic and/or therapeutic methods of using the panel are provided.